这是一个低剂量CTX+IL2维持化疗有效小细胞肺癌的实验，实验结果显示维持治疗没有优势，只有那些接受预防性放疗的病人PFS、OS有延长趋势。但我认为这个实验的用药方式有问题，维持治疗在于低剂量而持久，这个实验设计的剂量不低，所以用药时间就不能持久，每次用药间隔差不多一个月呢，如何实现持续免疫提升和抗血管生成？
http://meetinglibrary.asco.org/content/94245-114
Background: huKS-IL2 immunocytokine is a humanized antibody specific for EpCAM, fused at its Fc end to two molecules of IL2. Results of a phase 1b study of huKS-IL2 plus low-dose CTX, and preclinical data, provided a rationale to evaluate this combination in SCLC, which is often EpCAM-positive.
Methods: Patients (pts) with ED-SCLC responding (PR/CR) to 4 cycles of first-line Pt-based chemotherapy were randomized 1,5:1 to receive huKS-IL2/CTX or best supportive care (BSC). Pts in the huKS-IL2/CTX arm received six 21-day cycles of CTX 300 mg/m2 on day (d) 1, and 1.5 mg/m2/d huKS-IL2 on d2–4, followed by 21-d cycles of CTX on d1 and huKS-IL2 on d2 until progression. Pts were stratified for prophylactic cranial irradiation (PCI) and response to chemotherapy. Primary endpoint was PFS rate at 6 months (mo). Secondary endpoints included OS rates at 12 and 18 mo from start of Pt-based chemotherapy, median PFS and OS, safety, and immunogenicity.
Results: 108 pts (64 huKS-IL2/CTX arm, 44 BSC arm) were randomized and treated. Baseline characteristics were balanced between arms; however, higher % of males (75 vs 61.4%) and of ECOG PS 0 (45.3 vs 38.6%) were observed in the active arm. Median age was 61.7 (32; 81) and 59.2 (45; 74) years in the active and BSC arm, respectively. Most pts were in PR at randomization (2 pts – 1 in each arm – had CR). PCI was used in 15 (23.4%) and 11 (25%) pts in the active and BSC arm, respectively. No significant differences in PFS or OS were observed in the active vs BSC arm: PFS rate was 6.4 vs 12.2%; median PFS was 1.5 vs 1.4 mo; OS rates at 12 and 18 mo were 52 vs 61% and 24 vs 29%, respectively; median OS was 12.3 vs 14.1 mo. One PR (45% reduction vs randomization baseline) was observed in the active arm. In a subset of pts who received PCI, median PFS was 1.7 vs 1.5 mo, median OS 21.5 vs 14.3 mo in the active vs BSC arm, respectively. AEs observed more frequently in the active arm were flu-like symptoms, rash, hypotension, lymphopenia, LFT and creatinine elevations; all Grade 3/4 AEs related to huKS-IL2 were reversible/manageable.
Conclusions: HuKS-IL2/CTX was well tolerated, but showed no benefit in pts with ED-SCLC in PR/CR after chemotherapy. A trend for improved PFS and OS was observed in pts who received prior PCI.
|
肺腺癌10年，伏美替尼 心血管副作用
奶奶78岁，肺腺癌10年，2017.7-2023.7第一代靶向药凯美纳6年，2023.7至今伏美替尼1年
阿法替尼13个月，达克替尼5个月，目
2021年3月的最后一天，很平常的一天，一份CT报告打破了这平静的生活！也许再过一天，
求助，伏美替尼是在缓慢耐药吗？接下
基本情况
奶奶78岁，2014.7行肺腺癌手术，术后病理 浸润性肺癌，1.5*1.5cm，脏层胸膜
各位老师，帮忙看看我的问题，求帮助
父亲去年2023年2月份体检发现肺癌 晚期，免疫治疗一年，用药欧迪沃 期间病灶一直稳定
奥希替尼并非肺癌“万能解”，患者如
作者：Tony
在肺癌中，EGFR的突变以19号外显子缺失突变（19Del）和21号外显子的L858R
显身卡
